Amgen shares pare losses as drugmaker sees no bone safety concerns in obesity drug
CEO Bob Bradway said Amgen is "well advanced" in preparing to launch a Phase 3 testing round of MariTide in order to have enough data to allow the drug to receive approval from regulators. Amgen has also begun to examine a different weight-loss drug candidate, although few details have been disclosed, Reuters reported.
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...
according to Amgen. The drug was given as a subcutaneous injection every four weeks in the study, and showed a clear dose response with a 7.2% weight loss in the lowest dose group (140 mg ...
A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...
Investors are still waiting for Amgen's new weight loss drug, MariTide (formerly AMG133), its injectable obesity drug. MariTide's early stage testing showed an average of 14.5% weight ...
Amgen stock soared as much as 16% on Friday after it reported first-quarter earnings. The company talked up its experimental GLP-1 weight-loss drug, MariTide. The new weight loss drug ...
“A successful obesity drug could move growth into double-digit territory,” says Morningstar analyst Karen Andersen. Amgen shares offer investors a cheaper way to play the weight-loss ...
The drug will still likely have the intestinal side effects common to GLP-1 drugs, but those symptoms may be more manageable with less frequent treatments. Amgen's success in the weight loss ...
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback